首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1917749

血友病市場－2026-2031年預測

Hemophilia Market - Forecast from 2026 to 2031

出版日期: 2026年01月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

血友病市場預計將從 2025 年的 122.85 億美元成長到 2031 年的 178.46 億美元，複合年成長率為 6.42%。

血友病市場是全球孤兒藥和罕見病治療行業中一個專業且充滿活力的細分市場，專注於治療A型血友病A（VIII因子缺乏症）和B型血友病（IX因子缺乏症）。這些遺傳性出血性疾病的特徵是某些凝血因子缺乏，導致出血時間延長、關節和肌肉自發性出血，以及危及生命的併發症。該市場已從基本的血漿衍生因子替代療法發展到包括先進的重組因子濃縮物、半衰期延長產品、非因子療法和開創性的基因療法。市場成長的促進因素包括龐大的患者群體、疾病帶來的巨大臨床負擔，以及旨在改善治療效果和生活品質的大量創新治療方法。

主要市場成長要素

血友病的終身慢性特徵及其相關的嚴重併發症是成長要素。若不進行適當治療，患者將面臨反覆關節內出血（血腫）、疼痛性關節病變、慢性疼痛和嚴重殘疾。顱內出血和其他嚴重出血事件的風險始終存在。這種高發病率使得人們迫切需要有效的預防性和按需治療方案來預防出血和控制自發性出血，從而支撐了對治療產品的持續需求。

持續不斷的變革性治療創新正在滿足這項臨床需求。市場模式經歷了數代產品的演變，從標準的重組凝血因子製劑，到減少靜脈注射的長效凝血因子濃縮物（EHL），再到非凝血因子療法，例如可模擬凝血因子VIII功能的雙特異性單株抗體emicizumab，該抗體可皮下注射。其中最重要的創新是單劑量基因療法的出現，旨在永續地、甚至可能根治性提高體內凝血因子水平。這一不斷發展的研發管線正在重新定義治療模式，並創造巨大的市場價值。

此外，已開發市場健全的監管和報銷機制為這些高成本治療方法的市場進入提供了支持。血友病是一種罕見疾病，擁有完善的治療指南，這有助於監管機構進行審查，並讓支付方認知到該疾病存在巨大的未滿足醫療需求。政府政策、專業的血友病治療中心和患者權益倡導組織共同努力，確保患者能夠獲得標準療法和新型療法，從而創造出有利於新治療方法引入的環境，即使這些療法價格昂貴。

主要市場限制因素

市場面臨的最大限制因素是治療費用極為高昂，尤其是基因療法等新型先進療法。這些單次治療的費用可能高達數百萬美元，為醫療預算、支付者和健康技術評估機構帶來了巨大挑戰。這一成本壁壘限制了患者獲得治療的機會，造成了醫療體系之間的不平等，並且需要複雜的按績效付費合約和支付模式來管理支付方的財務風險。

其他阻礙因素包括可能出現抑制劑（針對因子濃縮物的中和抗體），這會使治療複雜化並增加成本；以及基因療法等新興治療方法固有的複雜性和風險，包括長期安全性的不確定性和患者反應的個體差異。這些因素造成了臨床和經濟上的不確定性，並可能減緩其推廣應用的速度。

區域展望：北美市場表現強勁

預計北美將繼續在全球血友病市場佔據主導地位。這一地位歸功於該地區完善且涵蓋範圍廣的血友病治療中心網路、較高的診斷和治療率、優惠的專科藥物報銷政策，以及眾多大型生物製藥公司推動創新。該地區的患者和醫療服務提供者通常樂於採用者新治療方法，且支付體系歷來支持高成本。這些因素鞏固了北美作為新產品上市和產生收入關鍵市場的地位。

The hemophilia market is a specialized and dynamic segment within the global orphan drug and rare disease therapeutics industry, focused on the treatment of hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency). This inherited bleeding disorder is characterized by a deficiency in specific clotting factors, leading to prolonged bleeding episodes, spontaneous hemorrhages into joints and muscles, and the risk of life-threatening complications. The market has evolved from basic plasma-derived factor replacement to include advanced recombinant factor concentrates, extended half-life products, non-factor therapies, and pioneering gene therapies. Market growth is driven by the established patient population, the severe clinical burden of the disease, and a robust pipeline of innovative treatments aimed at improving outcomes and quality of life.

Primary Market Growth Drivers

A foundational driver is the lifelong, chronic nature of hemophilia and its severe associated complications. Without adequate treatment, patients face recurrent bleeding into joints (hemarthroses), leading to painful arthropathy, chronic pain, and significant disability. The risk of intracranial and other critical bleeds presents a constant threat. This high morbidity creates an unwavering need for effective prophylactic and on-demand therapies to prevent bleeds and manage breakthrough events, sustaining a consistent demand for treatment products.

This clinical imperative is met by a landscape of continuous and transformative therapeutic innovation. The market has progressed through several generations of products: standard recombinant factors, extended half-life (EHL) factors requiring less frequent intravenous infusion, and non-factor therapies like emicizumab, a bispecific monoclonal antibody that mimics factor VIII function and allows for subcutaneous administration. The most significant innovation is the emergence of one-time gene therapies, which aim to provide a durable, potentially curative elevation of endogenous clotting factor levels. This pipeline evolution is redefining treatment paradigms and creating substantial market value.

Furthermore, strong regulatory and reimbursement pathways in developed markets support market access for these high-cost therapies. Hemophilia is a well-characterized orphan disease with clear treatment guidelines, facilitating regulatory review and payer recognition of the high unmet medical need. Government policies, specialized hemophilia treatment centers, and advocacy groups work to ensure patient access to standard-of-care and novel treatments, creating a supportive environment for the adoption of new therapies despite their premium pricing.

Key Market Restraints

The most significant constraint on the market is the extraordinarily high cost of therapy, particularly for novel advanced treatments like gene therapies. These one-time treatments carry price tags in the multi-million-dollar range, presenting immense challenges for healthcare budgets, payers, and health technology assessment bodies. This cost barrier can limit patient access, create disparities between healthcare systems, and necessitate complex outcomes-based contracting and payment models to manage financial risk for payers.

Additional restraints include the potential for inhibitor development (neutralizing antibodies against factor concentrates), which complicates treatment and increases costs, and the inherent complexity and risk profile of emerging modalities like gene therapy, including long-term safety uncertainties and variability in patient response. These factors introduce clinical and economic uncertainties that can temper the pace of widespread adoption.

Geographical Outlook: North American Market Strength

North America is anticipated to hold a dominant share of the global hemophilia market. This position is attributed to the region's well-established network of comprehensive hemophilia treatment centers, high diagnosis and treatment rates, favorable reimbursement frameworks for specialty pharmaceuticals, and the presence of leading biopharmaceutical companies driving innovation. The region's patients and providers are typically early adopters of novel therapies, and its payer systems have historically supported the high cost of hemophilia care, solidifying its role as the primary market for new product launches and revenue generation.

Competitive Landscape and Therapeutic Segmentation

The competitive landscape includes long-standing plasma product specialists, large biotechnology firms, and emerging gene therapy companies. Competition is intense and revolves around clinical efficacy (annualized bleeding rate reduction), safety profile, dosing convenience (frequency and route of administration), and long-term value proposition.

The market is segmented by therapeutic class:

Replacement Factors (Standard and EHL): The traditional mainstay, competing on purity, half-life extension, and immuno-tolerance induction.
Non-Factor Therapies: Representing a paradigm shift with subcutaneous administration and a different mechanism of action.
Gene Therapies: The new frontier, offering a potential functional cure but with significant upfront cost and long-term data requirements.

Strategic focus for companies involves demonstrating superior real-world outcomes, developing comprehensive patient support services, and navigating the complex market access journey for ultra-orphan drugs.

Future Trajectory and Strategic Considerations

The hemophilia market is at an inflection point, transitioning from chronic replacement to potential durable solutions. The future will be defined by the real-world rollout and long-term follow-up of gene therapies, which will determine their ultimate value and place in the treatment sequence. Competition will intensify between gene therapy for hemophilia A and B and highly effective non-factor prophylactic regimens.

For industry participants, strategic success will depend on generating and communicating robust long-term durability and safety data for gene therapies, developing innovative financing and access models to overcome cost barriers, and tailoring strategies for different global markets with varying healthcare infrastructures. As the standard of care continues to rise, the hemophilia market will remain a high-value, innovation-driven arena where demonstrating transformative patient outcomes is paramount to achieving both clinical and commercial success.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Hemophilia Market Segmentation

By Disease Type
Hemophilia A
Hemophilia B
Others
By Therapy
Replacement Therapy
Gene Therapy
Others (Immune Tolerance Induction Therapy etc.)
By Product Type
Recombinant Coagulation Factor Concentrates
Plasma-derived Coagulation Factor Concentrates
Others (Desmopressin etc.)
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEMOPHILIA MARKET BY DISEASE TYPE

5.1. Introduction
5.2. Hemophilia A
5.3. Hemophilia B
5.4. Others

6. HEMOPHILIA MARKET BY THERAPY

6.1. Introduction
6.2. Replacement Therapy
6.3. Gene Therapy
6.4. Others (Immune Tolerance Induction Therapy etc.)

7. HEMOPHILIA MARKET BY PRODUCT TYPE

7.1. Introduction
7.2. Recombinant Coagulation Factor Concentrates
7.3. Plasma-derived Coagulation Factor Concentrates
7.4. Others (Desmopressin etc.)

8. HEMOPHILIA MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others